Target Information
Target General Information | Top | |||||
---|---|---|---|---|---|---|
Target ID |
T31595
(Former ID: TTDS00174)
|
|||||
Target Name |
Influenza Neuraminidase (Influ NA)
|
|||||
Synonyms |
STNA; NEU1; NANase; N-acylneuraminate glycohydrolase; Influ Sialidase
Click to Show/Hide
|
|||||
Gene Name |
Influ NA
|
|||||
Target Type |
Successful target
|
[1] | ||||
Disease | [+] 1 Target-related Diseases | + | ||||
1 | Influenza [ICD-11: 1E30-1E32] | |||||
Function |
Unlike other strains, A/WSN/33 neuraminidase binds and activates plasminogen into plasmin in the vicinity of HA so that activated plasmin cleaves HA rendering the virus infectious.
Click to Show/Hide
|
|||||
BioChemical Class |
Glycosylase
|
|||||
UniProt ID | ||||||
EC Number |
EC 3.2.1.18
|
|||||
Sequence |
MNPNQKIITIGSICMVVGIISLILQIGNIISIWISHSIQTGNQNHTGICNQGIITYNVVA
GQDSTSVILTGNSSLCPIRGWAIHSKDNGIRIGSKGDVFVIREPFISCSHLECRTFFLTQ GALLNDKHSNGTVKDRSPYRALMSCPVGEAPSPYNSRFESVAWSASACHDGMGWLTIGIS GPDNGAVAVLKYNGIITETIKSWRKKILRTQESECTCVNGSCFTIMTDGPSNGLASYKIF KIEKGKVTKSIELNAPNSHYEECSCYPDTGKVMCVCRDNWHGSNRPWVSFDQNLDYQIGY ICSGVFGDNPRPKDGPGSCGPVSADGANGVKGFSYRYGNGVWIGRTKSDSSRHGFEMIWD PNGWTETDSRFSVRQDVVAMTDRSGYSGSFVQHPELTGLDCMRPCFWVELIRGRPEEETI WTSGSIISFCGVNSDTVDWSWPDGAELPFTIDK Click to Show/Hide
|
Drugs and Modes of Action | Top | |||||
---|---|---|---|---|---|---|
Approved Drug(s) | [+] 3 Approved Drugs | + | ||||
1 | Oseltamivir | Drug Info | Approved | Influenza virus infection | [2] | |
2 | Peramivir | Drug Info | Approved | Influenza virus infection | [3] | |
3 | Zanamivir | Drug Info | Approved | Influenza virus infection | [2], [4] | |
Clinical Trial Drug(s) | [+] 3 Clinical Trial Drugs | + | ||||
1 | CS-8958 | Drug Info | Phase 3 | Influenza virus infection | [5] | |
2 | UX-001 | Drug Info | Phase 3 | Hereditary inclusion body myositis | [6] | |
3 | DAS-181 | Drug Info | Phase 2 | Influenza virus infection | [7] | |
Discontinued Drug(s) | [+] 2 Discontinued Drugs | + | ||||
1 | BCX-140 | Drug Info | Terminated | Influenza virus infection | [8] | |
2 | GS-3435 | Drug Info | Terminated | Influenza virus infection | [9] | |
Mode of Action | [+] 2 Modes of Action | + | ||||
Inhibitor | [+] 70 Inhibitor drugs | + | ||||
1 | Oseltamivir | Drug Info | [10], [11] | |||
2 | Peramivir | Drug Info | [1], [10] | |||
3 | Zanamivir | Drug Info | [10], [11] | |||
4 | CS-8958 | Drug Info | [1] | |||
5 | UX-001 | Drug Info | [12] | |||
6 | DAS-181 | Drug Info | [7], [13] | |||
7 | BCX-140 | Drug Info | [13], [14], [15] | |||
8 | (E,E)-1,7-Diphenyl-4,6-heptadien-3-one | Drug Info | [17] | |||
9 | (E,E)-5-Hydroxy-1,7-diphenyl-4,6-heptadien-3-one | Drug Info | [17] | |||
10 | (S)-1,7-Diphenyl-6(E)-hepten-3-ol | Drug Info | [17] | |||
11 | 2,4-Deoxy-4-Guanidino-5-N-Acetyl-Neuraminic Acid | Drug Info | [15] | |||
12 | 2-Deoxy-2,3-Dehydro-N-Acetyl-Neuraminic Acid | Drug Info | [12] | |||
13 | 4-(Acetylamino)-3-Amino Benzoic Acid | Drug Info | [12] | |||
14 | 4-(ACETYLAMINO)-3-HYDROXY-5-NITROBENZOIC ACID | Drug Info | [18] | |||
15 | 4-(ACETYLAMINO)-5-AMINO-3-HYDROXYBENZOIC ACID | Drug Info | [18] | |||
16 | 4-Amino-2-Deoxy-2,3-Dehydro-N-Neuraminic Acid | Drug Info | [15] | |||
17 | 8-DEOXYGARTANIN | Drug Info | [19] | |||
18 | A-192558 | Drug Info | [20], [21], [22] | |||
19 | A-315675 | Drug Info | [20], [21], [22] | |||
20 | Alpha-D-Mannose | Drug Info | [12] | |||
21 | APIGENIN | Drug Info | [23] | |||
22 | BCX-1827 | Drug Info | [20], [21], [22] | |||
23 | BCX-1898 | Drug Info | [20], [21], [22] | |||
24 | BCX-1923 | Drug Info | [20], [21], [22] | |||
25 | Beta-D-Mannose | Drug Info | [12] | |||
26 | CALOPOCARPIN | Drug Info | [24] | |||
27 | Cristacarpin | Drug Info | [24] | |||
28 | CUDRATRICUSXANTHONE | Drug Info | [25] | |||
29 | Cudratricusxanthone F | Drug Info | [25] | |||
30 | Cudraxanthone D | Drug Info | [25] | |||
31 | Cudraxanthone L | Drug Info | [25] | |||
32 | Cudraxanthone M | Drug Info | [25] | |||
33 | Cyclopentane amide derivatives 1 | Drug Info | [20], [21], [22] | |||
34 | Cyclopentane amide derivatives 2 | Drug Info | [20], [21], [22] | |||
35 | Cyclopentane amide derivatives 3 | Drug Info | [20], [21], [22] | |||
36 | Cyclopentane amide derivatives 4 | Drug Info | [20], [21], [22] | |||
37 | DEMETHYLMEDICARPIN | Drug Info | [24] | |||
38 | ERYSTAGALLIN A | Drug Info | [24] | |||
39 | Erysubin D | Drug Info | [24] | |||
40 | Erysubin E | Drug Info | [24] | |||
41 | Erythribyssin D | Drug Info | [24] | |||
42 | Erythribyssin L | Drug Info | [24] | |||
43 | Erythribyssin M | Drug Info | [24] | |||
44 | Erythribyssin O | Drug Info | [24] | |||
45 | Eryvarin D | Drug Info | [24] | |||
46 | FANA | Drug Info | [20], [21], [22] | |||
47 | Fucose | Drug Info | [12] | |||
48 | Gamma-mangostin | Drug Info | [19] | |||
49 | GARCINONE D | Drug Info | [19] | |||
50 | GARTANIN | Drug Info | [19] | |||
51 | GOSSYPETIN | Drug Info | [23] | |||
52 | GS4071 | Drug Info | [20], [21], [22] | |||
53 | HERBACETIN | Drug Info | [23] | |||
54 | ISONEORAUTENOL | Drug Info | [24] | |||
55 | KAEMPFEROL | Drug Info | [23] | |||
56 | KATSUMADAIN A | Drug Info | [17] | |||
57 | Lactose | Drug Info | [12] | |||
58 | MACLURAXANTHONE | Drug Info | [25] | |||
59 | MANGIFERIN | Drug Info | [25] | |||
60 | MANGOSTANIN | Drug Info | [19] | |||
61 | MANGOSTANOL | Drug Info | [19] | |||
62 | MANGOSTENONE F | Drug Info | [19] | |||
63 | MANGOSTENONE G | Drug Info | [19] | |||
64 | MANGOSTIN | Drug Info | [19] | |||
65 | NEORAUTENOL | Drug Info | [24] | |||
66 | O-Sialic Acid | Drug Info | [18] | |||
67 | PHASEOLIN | Drug Info | [24] | |||
68 | PHASEOLLIDIN | Drug Info | [24] | |||
69 | RHODIOLININ | Drug Info | [23] | |||
70 | SMEATHXANTHONE A | Drug Info | [19] | |||
Modulator | [+] 1 Modulator drugs | + | ||||
1 | GS-3435 | Drug Info | [16], [13] |
Different Human System Profiles of Target | Top |
---|---|
Human Similarity Proteins
of target is determined by comparing the sequence similarity of all human proteins with the target based on BLAST. The similarity proteins for a target are defined as the proteins with E-value < 0.005 and outside the protein families of the target.
A target that has fewer human similarity proteins outside its family is commonly regarded to possess a greater capacity to avoid undesired interactions and thus increase the possibility of finding successful drugs
(Brief Bioinform, 21: 649-662, 2020).
Human Similarity Proteins
|
There is no similarity protein (E value < 0.005) for this target
|
Chemical Structure based Activity Landscape of Target | Top |
---|---|
Drug Property Profile of Target | Top | |
---|---|---|
(1) Molecular Weight (mw) based Drug Clustering | (2) Octanol/Water Partition Coefficient (xlogp) based Drug Clustering | |
|
||
(3) Hydrogen Bond Donor Count (hbonddonor) based Drug Clustering | (4) Hydrogen Bond Acceptor Count (hbondacc) based Drug Clustering | |
|
||
(5) Rotatable Bond Count (rotbonds) based Drug Clustering | (6) Topological Polar Surface Area (polararea) based Drug Clustering | |
|
||
"RO5" indicates the cutoff set by lipinski's rule of five; "D123AB" colored in GREEN denotes the no violation of any cutoff in lipinski's rule of five; "D123AB" colored in PURPLE refers to the violation of only one cutoff in lipinski's rule of five; "D123AB" colored in BLACK represents the violation of more than one cutoffs in lipinski's rule of five |
Co-Targets | Top | |||||
---|---|---|---|---|---|---|
Co-Targets |
Target Poor or Non Binders | Top | |||||
---|---|---|---|---|---|---|
Target Poor or Non Binders |
Target Profiles in Patients | Top | |||||
---|---|---|---|---|---|---|
Drug Resistance Mutation (DRM) |
Target Affiliated Biological Pathways | Top | |||||
---|---|---|---|---|---|---|
KEGG Pathway | [+] 1 KEGG Pathways | + | ||||
1 | Other glycan degradation |
Target-Related Models and Studies | Top | |||||
---|---|---|---|---|---|---|
Target Validation | ||||||
Target QSAR Model |
References | Top | |||||
---|---|---|---|---|---|---|
REF 1 | Developing new antiviral agents for influenza treatment: what does the future hold Clin Infect Dis. 2009 Jan 1;48 Suppl 1:S3-13. | |||||
REF 2 | Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. | |||||
REF 3 | 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. | |||||
REF 4 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. | |||||
REF 5 | ClinicalTrials.gov (NCT00803595) A Multinational Phase III Study of CS-8958 (MARVEL). U.S. National Institutes of Health. | |||||
REF 6 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
REF 7 | Inhibition of neuraminidase inhibitor-resistant influenza virus by DAS181, a novel sialidase fusion protein. PLoS One. 2009 Nov 6;4(11):e7838. | |||||
REF 8 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006335) | |||||
REF 9 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005196) | |||||
REF 10 | Current and future antiviral therapy of severe seasonal and avian influenza. Antiviral Res. 2008 Apr;78(1):91-102. | |||||
REF 11 | Antiviral agents for influenza, hepatitis C and herpesvirus, enterovirus and rhinovirus infections. Med J Aust. 2001 Jul 16;175(2):112-6. | |||||
REF 12 | How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. | |||||
REF 13 | Neuraminidase inhibitors: zanamivir and oseltamivir. Ann Pharmacother. 2001 Jan;35(1):57-70. | |||||
REF 14 | CN patent application no. 104447481, Benzoic acid thiourea anti-influenza virus compounds as well as preparation method and use thereof. | |||||
REF 15 | DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41. | |||||
REF 16 | US patent application no. 2010,0081,713, Compositions and methods for treating viral infections. | |||||
REF 17 | Antiviral potential and molecular insight into neuraminidase inhibiting diarylheptanoids from Alpinia katsumadai. J Med Chem. 2010 Jan 28;53(2):778-86. | |||||
REF 18 | The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. | |||||
REF 19 | Xanthones with neuraminidase inhibitory activity from the seedcases of Garcinia mangostana. Bioorg Med Chem. 2010 Sep 1;18(17):6258-64. | |||||
REF 20 | Antiviral agents active against influenza A viruses. Nat Rev Drug Discov. 2006 Dec;5(12):1015-25. | |||||
REF 21 | Comparison of the anti-influenza virus activity of cyclopentane derivatives with oseltamivir and zanamivir in vivo. Bioorg Med Chem. 2005 Jun 2;13(12):4071-7. | |||||
REF 22 | Syntheses and neuraminidase inhibitory activity of multisubstituted cyclopentane amide derivatives. J Med Chem. 2004 Apr 8;47(8):1919-29. | |||||
REF 23 | Neuraminidase inhibitory activities of flavonols isolated from Rhodiola rosea roots and their in vitro anti-influenza viral activities. Bioorg Med Chem. 2009 Oct 1;17(19):6816-23. | |||||
REF 24 | Prenylated pterocarpans as bacterial neuraminidase inhibitors. Bioorg Med Chem. 2010 May 1;18(9):3335-44. | |||||
REF 25 | Characteristic of neuraminidase inhibitory xanthones from Cudrania tricuspidata. Bioorg Med Chem. 2009 Apr 1;17(7):2744-50. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.